GT Biopharma (GTBP) FCF Margin (2010 - 2015)

GT Biopharma (GTBP) posted quarterly FCF Margin of 6465.0% for Q2 2015, up 74.68% quarter-over-quarter from 25528.57% in Q1 2015.

GT Biopharma (GTBP) FCF Margin (2010 - 2015) Analysis & Trends

GT Biopharma (GTBP) has reported FCF Margin for 5 consecutive years, with 6465.0% the latest figure, recorded in Q2 2015.

In Q2 2015, FCF Margin changed N/A year-over-year to 6465.0%; the TTM figure through Mar 2016 stood at 15185.0% (down 2749214.0% YoY), while the FY2015 annual figure was 17251.85%, down 1098399.0% from the prior year.
FCF Margin rose to 6465.0% in Q2 2015 per GTBP's latest filing, from 25528.57% in the prior quarter.
Across five years, FCF Margin topped out at 173.98% in Q4 2012 and bottomed at 39300.0% in Q2 2011.
Historically, FCF Margin has averaged 12499.37% across 4 years, with a median of 6465.0% in 2015.
Annual changes were most pronounced in 2012 — FCF Margin tumbled 1846500 bps — and 2013, when it soared 1904318 bps.
GT Biopharma's FCF Margin stood at 10800.0% in 2011, then jumped by 102 bps to 173.98% in 2012, then slumped by 190 bps to 156.82% in 2013, then tumbled by 4023 bps to 6465.0% in 2015.
Business Quant data shows GTBP's FCF Margin at 6465.0% in Q2 2015, 25528.57% in Q1 2015, and 156.82% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	GT Biopharma	8.38 Mn	8.38 Mn	-	-

Download Data